Pictet Asset Management
RARE icon

Pictet Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pictet Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.7M Sell
603,571
-627,760
-51% -$14.1M 0.01% 617
2025
Q4 		$26.6M Sell
1,231,331
-226,856
-16% -$7.46M 0.03% 457
2025
Q3 		$44M Sell
1,458,187
-241,757
-14% -$7.25M 0.04% 347
2025
Q2 		$61.9M Buy
1,699,944
+290,745
+21% +$10.5M 0.06% 284
2025
Q1 		$52M Buy
1,409,199
+235,561
+20% +$9.8M 0.06% 298
2024
Q4 		$49.4M Buy
1,173,638
+653,088
+125% +$32.4M 0.05% 301
2024
Q3 		$28.3M Sell
520,550
-36,268
-7% -$1.85M 0.03% 403
2024
Q2 		$22.9M Sell
556,818
-479,556
-46% -$20.5M 0.03% 436
2024
Q1 		$48.5M Buy
1,036,374
+13,238
+1% +$624K 0.05% 313
2023
Q4 		$48.9M Buy
1,023,136
+153,748
+18% +$5.96M 0.05% 316
2023
Q3 		$31M Buy
+869,388
New +$34.4M 0.04% 362

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Pictet Asset Management's RARE Position: Q1 2026 in Review

Pictet Asset Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 51% in Q1 2026, selling an estimated $14.1M and leaving 603,571 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #617.

Pictet Asset Management first reported a position in RARE in Q3 2023 and has held it in 11 quarters since. The position peaked at $61.9M in Q2 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Pictet Asset Management held 603,571 shares of Ultragenyx Pharmaceutical worth $11.7M as of Q1 2026.
  • Pictet Asset Management sold 627,760 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $14.1M.
  • Ultragenyx Pharmaceutical made up 0.01% of Pictet Asset Management's portfolio in Q1 2026, its #617 holding.
  • Pictet Asset Management first reported a position in Ultragenyx Pharmaceutical in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's Ultragenyx Pharmaceutical position peaked at $61.9M in Q2 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.